Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX
Quoin Pharmaceuticals — Cellect Biotechnology — Investor Presentation (March 2017)
19 slides from Quoin Pharmaceuticals's investor presentation, Mar 23, 2017
Slide 1: Enabling Stem Cells Corporate Presentation 2017
Enabling Stem Cells Corporate Presentation 2017
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements . ” In some cases, these forward - looking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “inten
Slide 3: Investment Highlights
Investment Highlights NASDAQ:APOP • Cellect represents potentially transformational technology • Aims to provide unlimited quantity of Stem Cells for medical and research uses • More effective, safer and less costly transplant procedures using Cellect expected to drive initial commercial demand alre
Slide 4: Experienced Management Team / Advisors
Experienced Management Team / Advisors Dr. Shai Yarkoni MD, PhD, Co - Founder & CEO Senior executive in the biotechnology industry. Founder and CEO of Target - In Ltd., a cancer biotech therapeutics company. Founde d and, until recently, managed Bio - Negev. Eyal Leibovitz, CFO More than 25 years of
Slide 5: Regenerative Vs. Treatment medicine
Regenerative Vs. Treatment medicine The holy grail of medicine – stop fixing by chemicals, by poisons, radiation and massive surgery . Instead – replace the damaged tissues and parts with Stem Cells technology . 5
Slide 6: The challenge
The challenge For Stem Cells to “work” there is a need for Purity and Quantity minima. Nowadays, technology is incapable of efficiently isolating stem cells to provide the necessary purity and quantity prerequisites . For example, Bone Marrow transplants normally have a mix of both stem and mature c
Slide 7: The need
The need To enable mass market Stem Cells treatments there is an urgent, unmet need for ... Stem Cells as raw material . There is a clear need for enabling tools for rapid and cost effective manufacturing of quality Stem Cells . 7
Slide 8: Cellect has the enabling platform for mass-production of quality stem cells
Cellect Biotechnology Ltd. has the enabling platform for mass - production of quality stem cells 8
Slide 9: Unattractive Trade-offs with Current Procedures
Unattractive Trade - offs with Current Procedures Bone Marrow Transplant Donor Sample Lab Procedure Morphological Cell Selection HSCT Transplant Trade - offs Non - toxic & ineffective Effective & highly toxic > 50 % GvHD Incidence if no Biomarker selection Biomarker selection reduces mass of stem ce
Slide 10: Our solution
Our solution • Cellect’s procedure and containers create a closed hostile environment for rejection causing cells • Container walls are coated with a protein that triggers cell death or apoptosis in mature cells (ApoTainer®) • In contrast, stem cells flourish in environments where normal cells die •
Slide 11: Cellect in the Value Chain
Cellect in the Value Chain Stem Cell product high - level process Raw Material Selection Expansion Utilization Final Product Without Cellect’s technology this stage becomes a major barrier for mass market Stem Cell therapies and research 11 Cellect (2 hours) Currently days to weeks
Slide 12: Cellect Vs. Alternatives
Cellect Vs. Alternatives *Current Procedures *Cellect Risk of GvHD > 50% 0 – 10 % Parallel Chemotherapy Wide Minimal Rate of Infection High Low Procedure and hospitalization Months Days Procedure Cost ~ $70,000 *At least 50% less Total cost of procedure ~ $300,000 *At least 50% less * Company Estima
Slide 13: Business strategy
Business strategy • Cellect provides enabling technology • Aiming for strategic licensing deals (upfront, milestones & royalties) with the Pharma, Biotech and Medtech players • Medical proof of concept through consumable medical devices • First mover advantage in a (Company estimated) multi - billio
Slide 14: Business Model
Business Model 1. IP Licensing – Upfront fee + milestone payments 2. Royalties – Tiered on net sales per each customers’ unit Product sold (TBD separately with each customer). • Comparable companies with similar business models: • Moderna • Abgenix • Medarex 14
Slide 15: Clinical Program
Clinical Program 2016 2017 2018 2019 2020 Ph I/II GvHD Prophylaxis (ISR) ApoTainer Optimization Healthy Donors MSC Preclinical Ph I/II GvHD Prophylaxis (US) ApoTainer Pivotal Study Ph I/II MSC ApoGraft ApoTainer MSC 15
Slide 16: Phase I/II Clinical Trials
Phase I/II Clinical Trials Israel (Rambam Medical Center in cooperation with Shaarei Tzedek Hospital) Location Hematopoietic stem cell transplantation (HSCT) to Leukemia patients Open Label Trial 12 patients Trial group Safety and efficacy Trial Purpose 12 - 18 months Trial Length Agreement signed w
Slide 17: Strong IP Protection
Strong IP Protection 7 families of global patent applications ( 2 already approved) • Patent for the concept of using apoptosis - inducing agents for stem cells selection • Patents for composition of matter of ApoTainers™ • Patents covering methods of use • Patents covering method of manufacturing A
Slide 18: Summary
Summary NASDAQ:APOP • Cellect represents potentially transformational technology • Aims to provide unlimited quantity of Stem Cells for medical and research uses • More effective, safer and less costly transplant procedures using Cellect expected to drive initial commercial demand already in 2017 •
Slide 19: Thank you. Enabling Stem Cells
Thank you. ENABLING STEM CELLS 19
Cellect Biotechnology — Investor Presentation (March 2017) on 6ix